**9. References**


Head and Neck Psoriasis 103

Handa, S. (2010). Newer trends in the management of Psoriasis at difficult to treat locations: Scalp, palmoplantar disease and nails, *Indian J Dermatol Venereol Leprol,*76:634-44. Hayashi, M. ; Fujihara, K. ; Beder, L.B. ; Yamamoto, Y. ; Hotomi, M. & Yamanaka, N. (2009).

palmaris et plantaris, *Auris Nasus Larynx*, 36(5):578-85. Epub 2009 Mar 5. Hone, S.W. ; Donnelly, M.J. ; Powell, F. & Blayney, A.W. Clearance of recalcitrant Psoriasis

Karason, A. ; Gudjonsson, J.E. ; Jonsson, H.H. & (2005). Genetics of Psoriasis in Iceland:

Katsambas, A. ; Peris, K. ; Vena, G. ; Freidmann, P. ; Wozel, G. ; Daudén, E. ; Licu, D. ;

Krueger, G.G. (1999). New method being developed for assessing Psoriasis, *National* 

Magrey, M. & Khan MA. New insights into synovitis, acne, pustulosis, hyperostosis, and

Martin, P. (1997). Wound healing—aiming for perfect skin regeneration, *Science*, 276:75–81. Masmoudi,J. ; Maalej, I. ; Masmoudi, A. ; Rached, H. ; Rebai, A.; Turki, H. ; Jaoua, A. (2009).

McCormack, P.L. (2011). Calcipotriol/betamethasone dipropionate: a review of its use in the

Mengesha, Y.M. & Bennett, M.L. (2002). Pustular skin disorders: diagnosis and treatment,

Meyer, N. ; Viraben, R. & Paul, C. (2008). Addictions and Psoriasis: an example of the

Mrowietz, U. ; Macheleidt, O. & Eicke, C. (2011). Effective treatment and improvement of

Nakajima, H. ; Nakajima, K. ; Tarutani, M. ; Morishige, R. & Sano S. Kinetics of circulating

Naldi, L. ; Tognoni, G. & Cainelli, T. (1994). Analytic epidemiology in Psoriasis, *J Invest* 

Naldi, L. & Rzany, B. (2009). Psoriasis (chronic plaque), *Clin Evid (Online)* 9, pii: 1706.

10.1111/j.1610-0387.2011.07695.x. [Epub ahead of print].

Multicentre, Open-label, Phase IIIb/IV Trial, *Arch Drug Info,*2:66–70. Kircik, L. (2011). Salicylic Acid 6% in an ammonium lactate emollient foam vehicle in the treatment of mild-to-moderate scalp Psoriasis, *J Drugs Dermatol*, 10(3):270-3. Krell, J. ; Chen, Y. & Caro, I. (2008). Response of head and neck Psoriasis to efalizumab: A

*Dermatology*, July 30-August 3, 2008, Chicago, IL. Poster 2407.

osteitis (SAPHO) syndrome, *Curr Rheumatol Rep*, 11(5):329-33.

*Psoriasis Foundation Forum.,*5:4-5.

doi: 10.2165/11207300-000000000-00000.

*Am J Clin Dermatol.* 3(6): 389-400.

2008,135 Suppl 4:S259-62.

ahead of print].

*Dermatol,* 102: 19s-23s.

after tonsillectomy, *Clin Otolaryngol Allied Sci*, 21(6):546-7.

1185.

Pathogenic role of tonsillar lymphocytes in associated with HSP60/65 in Pustulosis

Evidence for linkage of subphenotypes to distinct loci, *J Invest Dermatol*.,124:1177-

Placchi, M. & De La Brassinne, M. (2009). Assessing the Impact of Efalizumab on Nail, Scalp and Palmoplantar Psoriasis and on Quality of Life: Results from a

pooled data analysis. Presented at: *Summer Meeting of the American Academy of* 

Alexithymia and Psoriasis: a case-control study of 53 patients, *Encephale*, 35(1) :10-7.

treatment of Psoriasis vulgaris of the trunk, limbs and scalp, *Drugs*, 16;71(6):709-30.

dermatologist's implication in preventive medicine? *Ann Dermatol Venereol,*

quality of life in patients with scalp Psoriasis by topical use of calcipotriol/betamethasone (Xamiol(®) -gel): results, *J Dtsch Dermatol Ges*, 12. doi:

Th17 cytokines and adipokines in Psoriasis patients, *Arch Dermatol Res,*17. [Epub

association with keratinocyte activation, proliferation, and keratinization, *Am J Pathol.* 162(3):963-75.


Boffetta, P. ; Gridley, G.; Lindelöf, B. (2001). Cancer Risk in a Population-Based Cohort of

Bolognia, J.L. ; Brewer, Y.P. & Cooper, D.L. (1991) Bazex syndrome (acrokeratosis paraneoplastica). An analytic review, *Medicine* (Baltimore) 70(4): 269-80. Boralevi, F. ; Marco-Bonnet, J. ; Lepreux, S. ; Buzenet, C. ; Couprie, B. & Taïeb, A. (2006). Hyperkeratotic head and neck Malassezia dermatosis, *Dermatology* 212(1): 36-40. Bowen, S.L. ; Bloor, B.K. ; Leigh, I.M. & Waseem, A. (2003). Adducin expression in

Callis Duffin, K. & Mease, P.J. (2011).Psoriasis and Psoriatic Arthritis Video Project 2010: a

Canto, A.M. ; Müller, H. ; Freitas, R.R. & Santos, P.S. (2010). Oral lichen planus (OLP): clinical and complementary diagnosis, *An Bras Dermatol*. 85(5): 669-75. Costa, S.C. ; Hirota S.K. ; Takahashi, M.D. ; Andrade, H. Jr. & Migliari, D.A. (2009). Oral

Daneshpazhooh, M. ; Moslehi, H. ; Akhyani, M. & Etesami, M. (2004). Tongue lesions in

Danilenko, D.M. (2008). Review Paper: Preclinical Models of Psoriasis, *Vet Pathol,* 45:563–

Farber, E.M. & Nall, L.(1992). Natural history and treatment of scalp Psoriasis, *Cutis*, 49:396-

Ferguson, P.J. ; Lokuta, M.A. ; El-Shanti, H.I. ; Muhle, L. ; Bing, X. & Huttenlocher, A. (2008).

Freedberg, I.M. ; Tomic-Canic, M. ; Komine, M. & Blumenberg, M. (2001). Keratins and the

Frentz, G. & Olsen, J.H. (1999). Malignant tumours and Psoriasis: a follow-up study, *Br J* 

Garcia-Valladares I.; Cuchacovich R.; Espinoza, L.R. (2011). Comparative assessment of

Gelfand, J.M. ; Mehta, N.N. & Langan, S.M. (2011). Psoriasis and cardiovascular risk:

Gonçalves, L.M. ; Bezerra Júnior, J.R. & Cruz, M.C. (2010). Clinical evaluation of oral lesions associated with dermatologic diseases, *An Bras Dermato,*. 85(2): 150-6. Gupta, A.K. ; Batra, R. ; Bluhm, R. (2004). Skin diseases associated with Malassezia species, *J* 

keratinocyte activation cycle, *J Invest Dermatol*, 116: 633–640.

ustekinumab, *Drug Design, Development and Therapy*,5 :41-49.

strength in numbers, part II. *J Invest Dermatol*, 131(5):1007-10.

Neutrophil dysfunction in a family with a SAPHO syndrome-like phenotype,

biologics in treatment of Psoriasis: drug design and clinical effectiveness of

report from the GRAPPA annual meeting, *J Rheumatol*, 38(3):562-3.

117 :1531–1537; doi:10.1046/j.0022-202x.2001.01520.x.

Bruce, A.J. & Rogers, 3rd R.S.. (2003). Oral Psoriasis, *Dermatol Clin*, 21:99-104.

Psoriasis: a controlled study, *BMC Dermatol*. 4(1): 16.

*Pathol.* 162(3):963-75.

lesions. *Int J Dermatol*, 38: 579–581.

*Oral Cir Bucal* 14(8): e371-5.

*Arthritis Rheum*, 58:3264-3269.

*Am Acad Dermatol*, 51:785-798.

*Dermatol*. 140(2): 237-42.

575.

400.

association with keratinocyte activation, proliferation, and keratinization, *Am J* 

Patients Hospitalized for Psoriasis in Sweden, *Journal of Investigative Dermatology,*

cutaneous and oral lesions: alpha- and beta-adducin transcripts down-regulate with keratinocyte differentiation in stratified epithelia, *J Pathol*. 201(1): 119-26. Brook, I. ; Frazier, E.H. & Yeager, J.K. (1999). Microbiology of infected pustular Psoriasis

lesions in 166 patients with cutaneous Psoriasis: a controlled study, *Med Oral Patol* 


Head and Neck Psoriasis 105

Takahara, M. ; Kishibe, K. ; Nozawa, H. ; Harabuchi, Y. (2005). Increase of activated T-cells

Tokura, Y. ; Mori, T. & Hino, R. (2010). Psoriasis and other Th17-mediated skin diseases, *J* 

Tsai, T.F. ; Wang, T.S. ; Hung, S.T. ; Tsai, P.I. ; Schenkel, B. ; Zhang, M. ; Tang, C.H. (2011).

Ueda, S. ; Takahara, M. ; Tohtani, T. ; Yoshizaki, T. ; Kishibe, K. ; Harabuchi, Y. (2010). Up-

van de Kerkhof, P.C. ; Kleinpenning, M. & Gerritsen, R. (2009).Scalp Psoriasis. In: Koo J, Lee

Waseem, A.; Dogan, B. ; Tidman, N. ; Alam, Y. ; Purkis, P. ; Jackson, S. ; Lalli, A. ;

downregulation in activated keratinocytes, *J Invest Dermatol.* 112(3): 362-9. Weathers, D.R. ; Baker, G. ; Archard, H.O.& Burkes, Jr. E.J. (1974). Psoriasiform lesions of the

Wilson, J.K. ; Al-Suwaidan, S.N. ; Krowchuk, D. & Feldman, S.R. (2003). Treatment of

Wittkowski, K.M. ; Leonardi, C. ; Gottlieb, A. ; Menter, A. ; Krueger, G.G. ; Tebbey, P.W. ;

Wu, Y. ; Lin, Y. ; Liu, H.J. ; Huang, C.Z. ; Feng, A.P. & Li, J.W. (2010). Childhood Psoriasis: a

Yaghoobi, R. ; Feily, A. ; Behrooz, B. ; Yaghoobi, E. & Mokhtarzadeh, S. (2010). Palpebral

Yoshizaki, T. ; Bandoh, N. ; Ueda, S. ; Nozawa, H.; Goto, T. ; Kishibe, K. ; Takahara, M. &

study of 137 cases from central China, *World J Pediatr*,6(3):260-4.

erythematosus, *ScientificWorldJournal.* 10: 2130-1.

review of the literature, *Pediatr Dermatol*, 26(5):497-505.

Valdimarsson, H. (2007).The genetic basis of Psoriasis, *Clin Dermatol*; 25: 563-7.

*UOEH*, 32(4):317-28.

Healthcare.

*Oral Pathol*, 37: 872-888.

*Dermatol*, 20(1):11-5.

doi:10.1371/journal.pone.0020279.

Taiwan, *J Dermatol Sci*, 63:40-6.

30(6):861-71. Epub 2010 Aug 17.

and up-regulation of Smad7 without elevation of TGF-beta expression in tonsils from patients with pustulosis palmaris et plantaris, *Clin Immunol*, 115(2):192-9. Tlougan, B.E. ; Podjasek, J.O. ; O'Haver, J. ; Cordova, K.B. ; Nguyen, X.H. ; Tee, R. ;

Pinckard-Hansen, K.C. & Hansen, R.C. Chronic recurrent multifocal osteomyelitis (CRMO) and synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with associated neutrophilic dermatoses: a report of seven cases and

Epidemiology and comorbidities of psoriasis patients in a national database in

regulation of ß1 integrin on tonsillar T cells and its induction by in vitro stimulation with α-streptococci in patients with pustulosis Palmaris et Plantaris, *J Clin Immunol*,

CS, Lebwohl M, editors. *Mild-To-Moderate Psoriasis*. 2 nd ed. London: Informa

Machesney, M. & Leigh, I.M. (1999). Keratin 15 expression in stratified epithelia:

oral mucosa (with emphasis on ''ectopic geographictongue''), *Oral Surg Oral Med* 

Psoriasis in children: is there a role for antibiotic therapy and tonsillectomy? *Pediatr* 

Belasco, J. ; Soltani-Arabshahi, R. ; Gray, J. ; Horn, L. & Krueger J.G. (2011) Clinical Symptoms of Skin, Nails, and Joints Manifest Independently in Patients with Concomitant Psoriasis and Psoriatic Arthritis, *PLoS ONE* 6(6): e20279.

involvement as a presenting and sole manifestation of discoid lupus

Harabuchi, Y. (2009). Up-regulation of CC chemokine receptor 6 on tonsillar T cells and its induction by in vitro stimulation with α-streptococci in patients with pustulosis palmaris et plantari, *Clinical and Experimental Immunology*, 157: 71–82.


Niessen, F.B. ; Andriessen, M.P. ; Schalkwijk, J. ; Visser, L. & Timens, W. (2001).

Noiles, K. & Vender, R. (2008). Treatment of severe facial Psoriasis with adalimumab, *J* 

Nozawa, H. ; Kishibe, K. ; Takahara, M. & Harabuchi, Y. (2005). Expression of cutaneous

Ogunmakin, K.O. ; Rashid, R.M. (2011) Alopecia: the case for medical necessity, *Skinmed*,

Owen, C.M. ; Chalmers, R.J. ; O'Sullivan, T. & Griffiths, C.E. (2000). Antistreptococcal

Puig, L. ; Ribera, M. ; Hernanz, J.M. ; Belinchón, I. ; Santos-Juanes, J. ; Linares, M. ; Querol,

Puzenat E. ; Bronsard, V. ; Prey, S. ; Gourraud, P.A. ; Aractingi, S. ; Bagot, M. ; Cribier, B. ;

Rossi, A. ; Mandel, V.D. ; Garelli, V. ; Mari, E. ; Fortuna, M.C. ; Carlesimo, M. ; Richetta, A. ;

Rozin, A.P. (2009). SAPHO syndrome: Is a range of pathogen-associated rheumatic diseases

Santos-Silva, A.R. ; Correa, M.B. ; Vargas, P.A. ; Almeida, O.P. & Lopes, M.A. (2010). Bazex

Schilling, F. & Kessler S. (2000). SAPHO syndrome : clinico-rheumatologic and radiologic

Squier, C.A. ; Johnson, N.W. & Hopps, R.M. (1976). Human Oral Mucosa: Development, Structure and Function. Oxford, *Blackwell Scientific Publications*, pp 7–44. Stefanaki, C. ; Lagogianni, E.; Kontochristopoulos, G. ; Verra, P.; Barkas, G. ; Katsambas, A.

Stein, L. (2005). Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of Psoriasis, *J Am Acad Dermatol*. 53(1 Suppl 1):S39-49.

extended? *Arthritis Research & Therapy*, 11:131 (doi:10.1186/ar2837).

persistent ulcerations, *Head Neck Pathol*. 4(4): 312-7.

Dermatology and Venereology, *Actas Dermosifiliogr*, 101(10):827-46.

Oppenheim, M. (1903). Psoriasis mucosae oris, *Monatsschr Prakt Dermatol*, 37: 481.

scars, *J Pathol*, 194:207–216.

*Drugs Dermatol*, 7(12):1165-7.

9(2): 79-84.

*Rev*;(2):CD001976.

24 (Suppl 2):10-6.

59 (1) :1-28.

*Dermatol* 9. [Epub ahead of print].

*Dermatol Venereol.* 25(4): 417-21.

plantaris (PPP), *Clin Immunol*, 116(1):42-53.

Keratinocyte-derived growth factors play a role in the formation of hypertrophic

lymphocyte-associated antigen (CLA) in tonsillar T-cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et

interventions for guttate and chronic plaque Psoriasis, *Cochrane Database Syst* 

I. ; Colomé, E. & Caballé, G. (2010). Treatment of scalp Psoriasis: review of the evidence and Delphi consensus of the Psoriasis Group of the Spanish Academy of

Joly, P. ; Jullien, D. ; Le Maitre, M. ; Paul, C. ; Richard-Lallemand, M.A. ; Ortonne, J.P. ; Aubin, F. (2010). What are the best outcome measures for assessing plaque Psoriasis severity? A systematic review of the literature, *Eur Acad Dermatol Venereol*,

Scarnò, M. ; Trucchia, A. & Calvieri, S. (2011). Videodermoscopy Scalp Psoriasis Severity Index (VSCAPSI): A useful tool for evaluation of scalp Psoriasis, *Eur J* 

syndrome (acrokeratosis paraneoplastica) diagnosed in a patient with oral

differentiatiation and classification of a patient sample of 86 cases, *Z Rheumatol*,

& Katsarou, A. (2011). Psoriasis in children: a retrospective analysis, *J Eur Acad* 


**7** 

*Italy* 

**Metabolic Features in Psoriasis** 

*Dermatologic Clinic, Polythecnic University of Marche Region* 

Giulia Ganzetti, Anna Campanati, Giulia Liberati and Annamaria Offidani

Psoriasis is a chronic inflammatory disease affecting about 3% of the worldwide population

Recent findings have shown that the previous concept " psoriasis as a disease of healthy people" must be revisited into psoriasis as a complex entity with multisistemic involvement. Although the overall mortality attributed to psoriasis is about 0.64 deaths per 100 000 psoriatic patients annually in the USA, erythrodermic and generalized pustular soriasis, are associated with a greater risk of mortality and morbidity (Boyd AS et al, 1989; Prystowsky

Psoriasis can be associated with other disease, such as metabolic syndrome, which may have

The aim of this chapter is to focus on two newly emergent comorbidities in psoriatic

The metabolic syndrome (MetS) is a cluster of risk factors including obesity, atherogenic dyslipidaemia, hypertension, glucose intolerance and a proinflammatory and prothrombotic state predisposing the patients to cardiovascular diseases (CVD), type 2 diabetes (DM),

Furthermore, it has recently been suggested that the metabolic syndrome might be a risk

The MetS prevalence in Western Europe population ranges from 15% to 35% and it strictly correlates with age, increasing sharply after the age of 60 (Gisondi et al, 2007).

The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) have proposed the criteria for the metabolic syndrome diagnosis; other organizations, such as The World Health Organization (WHO) and the European Group on Insulin resistance, agree with it in the essential components, differing from it in the details and criteria (Chung

According to NCEP ATPIII the diagnosis of MetS requires at least three of these following

patients, the cardiovascular disease (CVD) and the metabolic syndrome (MetS).

a major impact on quality of life, morbidity and mortality.

factor for cancer, in particular colon cancer (Gottlieb A et al, 2007).

**1. Introduction** 

JH et al, 1995).

CP et al, 2005).

criteria:

(Gottlieb A et al, 2007).

**2. The metabolic syndrome** 

renal failure and stroke (Gisondi et al, 2007).

